Renuvion Safely and Effectively Treats Lax Skin in Trial
In a Phase II study, the Renuvion device improved the appearance of lax skin in 82.5% of subjects after 6 months.
In a Phase II study, the Renuvion device improved the appearance of lax skin in 82.5% of subjects after 6 months.
Plastic surgeon Gaurav Bharti, MD, FACS, and Cytrellis Biosystems CEO Denise Dajles, D.Eng, share clinical and strategic insights into how ellacor is changing the way skin laxity and facial wrinkles are treated without surgery or thermal energy.
The phase IV trial evaluated outcomes of Sculptra plus Restylane Lyft or Contour in patients with facial volume loss due to weight loss medications.
PDO Max, Inc., a provider of U.S. FDA-cleared polydioxanone (PDO) threads-in-cannula medical devices for non-surgical facial tissue repositioning, announces that its PDO device continues to comply with the Medical Device Single Audit Program, or MDSAP, certification.
Read MoreA report published by Global Industry Analysts expects the global aesthetic services market to hit $23.3 billion by 2026.
Read MoreThanks to a recent viral TikTok video, eyelid lift surgeries may be the next rising trend in plastic surgery.
Read More